ifosfamide has been researched along with Leukocytopenia in 63 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the toxicity and efficacy of concurrent chemoirradiation with cisplatin followed by adjuvant ifosfamide, 5-fluorouracil and leucovorin in patients with stage IVb nasopharyngeal carcinoma (NPC) PATIENTS AND METHODS: Between October 1998 and August 2001, 35 Chinese patients with stage IVb NPC (N3a:12, N3b:23) were treated with by concurrent chemoirradiation using cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with 1." | 9.11 | A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma. ( Au, GK; Chua, DT; Sham, JS, 2004) |
| "5 g m(-2), carboplatin 100 mg m(-2) and etoposide 150 mg m(-2), days 1-4, q 28 days, G-CSF 5 microg kg(-1) starting from day 6) alone and in combination with regional hyperthermia (RHT) in soft tissue sarcoma (STS) refractory to previous standard doxorubicin-ifosfamide-based chemotherapy." | 9.11 | Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults. ( Abdel-Rahman, S; Fahn, W; Fiegl, M; Issels, RD; Schlemmer, M; Wendtner, CM, 2004) |
| "Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery." | 9.10 | Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002) |
| "Prolonged daily administration of oral etoposide has been reported to be active in refractory lymphoma." | 9.08 | Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. ( Ben-Shahar, M; Epelbaum, R; Haim, N, 1995) |
| "To evaluate the feasibility, toxicity and efficacy of the combination of (IFO) ifosfamide and epirubicin (EPI) given at conventional doses for monochemotherapy, we started a phase II study in advanced/metastatic soft tissue sarcoma patients." | 9.07 | Epirubicin and ifosfamide in advanced soft tissue sarcomas. ( Buonadonna, A; Carbone, A; Crivellari, D; De Paoli, A; Foladore, S; Frustaci, S; Monfardini, S; Morassut, S; Sorio, R, 1993) |
| "This study investigated the feasibility and efficacy of doxorubicin dose-escalated chemotherapy in combination with ifosfamide in patients with malignant mesothelioma." | 9.07 | A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. ( Corthouts, B; Dirix, LY; Prové, A; Schrijvers, D; van Marck, E; van Meerbeeck, J; van Oosterom, AT; Vermeire, P, 1994) |
| "One hundred and seventy-one patients with advanced soft tissue sarcoma entered a randomized crossover phase II study comparing cyclophosphamide (CYCLO) with a new analogue, ifosfamide (IFOS), both administered as 24 h i." | 9.06 | Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas. ( Blackledge, G; Bramwell, VH; Mouridsen, HT; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Van Oosterom, A, 1986) |
| "In the present study, we aimed to evaluate the safety and efficacy of DeVIC (dexamethasone, etoposide, ifosfamide and carboplatin) chemotherapy for the treatment of patients with primary central nervous system lymphoma (PCNSL)." | 7.77 | Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. ( Fujii, M; Ito, M; Momota, H; Motomura, K; Natsume, A; Wakabayashi, T, 2011) |
| "Recurrent and refractory neuroblastoma responds well to chemotherapy regimen of ifosphamide plus carboplatin." | 7.73 | [Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma]. ( Ling, JY; Sun, XF; Wang, ZH; Xia, Y; Zhen, ZJ, 2006) |
| "A total of 33 patients (median age, 44 years) with high-grade, adult soft-tissue sarcoma were treated with etoposide given at 600 mg/m2 in a 72-h continuous infusion and ifosfamide given at 1500 mg/m2 per day for 3 days every 3 weeks." | 7.69 | Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide. ( Saeter, G; Solheim, OP; Talle, K, 1995) |
| "The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft tissue sarcoma." | 7.68 | Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Stewart, W; Thomas, D; van Oosterom, AT; Verweij, J, 1990) |
| "Fourteen evaluable patients with gynecologic adenocarcinoma (7 ovarian, 4 endometrial, 2 peritoneal and one breast cancer) were treated with ifosfamide (1 g/m2 X 5 days), adriamycin (50 mg/m2) and cisplatin (50 mg/m2) combined chemotherapy (IAP)." | 7.67 | Treatment of gynecological adenocarcinomas with a combination of ifosfamide, adriamycin and cisplatin. ( Nagasue, N; Nishida, T, 1988) |
| "Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients." | 7.67 | Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. ( Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E, 1986) |
| "Sixteen patients suffering from multiple myeloma in stage II/A and III/A according to Durie and Salmon underwent chemotherapy consisting of a total of three cycles of ifosfamide (3 g/m(2) on days 1 and 2 and epirubicine 80 mg/m(2) on day 1) and G-CSF (10 or 20 microg/kg body weight (BW) daily until harvesting)." | 6.70 | Ifosamide, epirubicin and granulocyte colony-stimulating factor: a regimen for successful mobilization of peripheral blood progenitor cells in patients with multiple myeloma. ( Arland, M; Bartsch, R; Florschütz, A; Franke, A; Höffkes, HG; Kahl, C; Lange, S; Leuner, S, 2001) |
| "In advanced soft tissue sarcomas of adults, single-agent doxorubicin is still the standard chemotherapy against which more intensive or new drug treatments should be compared." | 6.68 | Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. ( Buesa, J; Casali, P; Mouridsen, H; Rankin, E; Santoro, A; Somers, R; Spooner, D; Steward, W; Tursz, T; Verweij, J, 1995) |
| "Ifosfamide (5 g/m2) was compared with its parent analogue cyclophosphamide (1." | 6.67 | Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Bramwell, VH; Dombernowsky, P; Mouridsen, HT; Onsrud, M; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Verweij, J, 1993) |
| "Radiochemotherapy involving cisplatinum-based polychemotherapy is more toxic than radiotherapy in combination with temozolomide." | 5.48 | Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients. ( Bison, B; Bojko, S; Gielen, GH; Hoffmann, M; Kortmann, RD; Kramm, CM; Pietsch, T; Seidel, C; von Bueren, AO; Warmuth-Metz, M, 2018) |
| "Ifosfamide has been shown to be associated with encephalopathy in 10-40% of patients." | 5.43 | Severe post-treatment leukopenia associated with the development of encephalopathy following ifosfamide infusion. ( Isola, LM; Kim, SS; Oh, WK, 2016) |
| "To evaluate the toxicity and efficacy of concurrent chemoirradiation with cisplatin followed by adjuvant ifosfamide, 5-fluorouracil and leucovorin in patients with stage IVb nasopharyngeal carcinoma (NPC) PATIENTS AND METHODS: Between October 1998 and August 2001, 35 Chinese patients with stage IVb NPC (N3a:12, N3b:23) were treated with by concurrent chemoirradiation using cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with 1." | 5.11 | A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma. ( Au, GK; Chua, DT; Sham, JS, 2004) |
| "5 g m(-2), carboplatin 100 mg m(-2) and etoposide 150 mg m(-2), days 1-4, q 28 days, G-CSF 5 microg kg(-1) starting from day 6) alone and in combination with regional hyperthermia (RHT) in soft tissue sarcoma (STS) refractory to previous standard doxorubicin-ifosfamide-based chemotherapy." | 5.11 | Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults. ( Abdel-Rahman, S; Fahn, W; Fiegl, M; Issels, RD; Schlemmer, M; Wendtner, CM, 2004) |
| "Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery." | 5.10 | Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002) |
| "Since dose intensity of doxorubicin is correlated with the clinical response of patients with soft tissue sarcomas and since doxorubicin dose intensity may be compromised in combination chemotherapy, we evaluated the use of recombinant granulocytemacrophage colony-stimulating factor (rGM-CSF) to ameliorate myelosuppression and allow doxorubicin dose escalation in a phase I trial utilizing the MAID combination [Mesna 2." | 5.08 | GM-CSF did not allow doxorubicin dose escalation in the MAID regimen: a phase I trial. A Southwest Oncology Group study. ( Balcerzak, SP; Hicks, LG; Zalupski, M, 1996) |
| "Prolonged daily administration of oral etoposide has been reported to be active in refractory lymphoma." | 5.08 | Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. ( Ben-Shahar, M; Epelbaum, R; Haim, N, 1995) |
| "This study investigated the feasibility and efficacy of doxorubicin dose-escalated chemotherapy in combination with ifosfamide in patients with malignant mesothelioma." | 5.07 | A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. ( Corthouts, B; Dirix, LY; Prové, A; Schrijvers, D; van Marck, E; van Meerbeeck, J; van Oosterom, AT; Vermeire, P, 1994) |
| "To evaluate the feasibility, toxicity and efficacy of the combination of (IFO) ifosfamide and epirubicin (EPI) given at conventional doses for monochemotherapy, we started a phase II study in advanced/metastatic soft tissue sarcoma patients." | 5.07 | Epirubicin and ifosfamide in advanced soft tissue sarcomas. ( Buonadonna, A; Carbone, A; Crivellari, D; De Paoli, A; Foladore, S; Frustaci, S; Monfardini, S; Morassut, S; Sorio, R, 1993) |
| "One hundred and seventy-one patients with advanced soft tissue sarcoma entered a randomized crossover phase II study comparing cyclophosphamide (CYCLO) with a new analogue, ifosfamide (IFOS), both administered as 24 h i." | 5.06 | Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas. ( Blackledge, G; Bramwell, VH; Mouridsen, HT; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Van Oosterom, A, 1986) |
| "5%) nonmetastatic soft tissue sarcoma received neoadjuvant chemoradiotherapy with ifosfamide (1." | 3.83 | Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience. ( Agaimy, A; Croner, R; Fietkau, R; Hohenberger, W; Lettmaier, S; Ott, O; Semrau, S; Stubbe, F; Vassos, N, 2016) |
| "The stage-by-stage prognosis for cervical cancer patients has not improved in the past decades." | 3.77 | Neoadjuvant therapy for cervical cancer. ( Achterrath, W; Eiermann, W; Kuehnle, H; Meerpohl, HG, 1992) |
| "In the present study, we aimed to evaluate the safety and efficacy of DeVIC (dexamethasone, etoposide, ifosfamide and carboplatin) chemotherapy for the treatment of patients with primary central nervous system lymphoma (PCNSL)." | 3.77 | Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. ( Fujii, M; Ito, M; Momota, H; Motomura, K; Natsume, A; Wakabayashi, T, 2011) |
| "Recurrent and refractory neuroblastoma responds well to chemotherapy regimen of ifosphamide plus carboplatin." | 3.73 | [Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma]. ( Ling, JY; Sun, XF; Wang, ZH; Xia, Y; Zhen, ZJ, 2006) |
| "A total of 33 patients (median age, 44 years) with high-grade, adult soft-tissue sarcoma were treated with etoposide given at 600 mg/m2 in a 72-h continuous infusion and ifosfamide given at 1500 mg/m2 per day for 3 days every 3 weeks." | 3.69 | Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide. ( Saeter, G; Solheim, OP; Talle, K, 1995) |
| "Twelve patients with relapsed or refractory malignant lymphoma were treated with IMV-triple P regimen consisting of ifosfamide (IFM), mitoxantrone (MIT), vindesine (VDS), pepleomycin (PEP), procarbazine (PCZ) and prednisolone (PDN)." | 3.68 | [Salvage chemotherapy with IMV-triple P for relapsed or refractory malignant lymphoma]. ( Arai, N; Hara, A; Shirai, T; Umeda, M, 1991) |
| "The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft tissue sarcoma." | 3.68 | Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Stewart, W; Thomas, D; van Oosterom, AT; Verweij, J, 1990) |
| "Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients." | 3.67 | Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. ( Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E, 1986) |
| "Fourteen evaluable patients with gynecologic adenocarcinoma (7 ovarian, 4 endometrial, 2 peritoneal and one breast cancer) were treated with ifosfamide (1 g/m2 X 5 days), adriamycin (50 mg/m2) and cisplatin (50 mg/m2) combined chemotherapy (IAP)." | 3.67 | Treatment of gynecological adenocarcinomas with a combination of ifosfamide, adriamycin and cisplatin. ( Nagasue, N; Nishida, T, 1988) |
| "Eight patients with advanced germ cell cancer were treated with TIP that was originally reported by Motzer et al (1)." | 2.71 | Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer. ( Akaza, H; Hattori, K; Hinotsu, S; Kawai, K; Miyazaki, J; Shimazui, T; Tsukamoto, S, 2003) |
| "Sixteen patients suffering from multiple myeloma in stage II/A and III/A according to Durie and Salmon underwent chemotherapy consisting of a total of three cycles of ifosfamide (3 g/m(2) on days 1 and 2 and epirubicine 80 mg/m(2) on day 1) and G-CSF (10 or 20 microg/kg body weight (BW) daily until harvesting)." | 2.70 | Ifosamide, epirubicin and granulocyte colony-stimulating factor: a regimen for successful mobilization of peripheral blood progenitor cells in patients with multiple myeloma. ( Arland, M; Bartsch, R; Florschütz, A; Franke, A; Höffkes, HG; Kahl, C; Lange, S; Leuner, S, 2001) |
| " Our trial failed to demonstrate a significant improvement in response or survival when patients with metastatic NSCLC were treated, in addition to ifosfamide and mitomycin, by combination of moderate dosages of cisplatin and carboplatin instead of moderate dosage of cisplatin alone." | 2.69 | Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. ( Alexopoulos, CG; Baumöhl, J; Berghmans, T; Florin, MC; Klastersky, J; Koumakis, G; Lafitte, JJ; Mommen, P; Ninane, V; Paesmans, M; Schmerber, J; Sculier, JP; Thiriaux, J; Zacharias, C, 2000) |
| "Phlebitis was observed in 15 of 30 patients (50%) who did not have central implantable venous systems." | 2.68 | Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma. ( Amato, S; Barbieri, M; Cuevas, M; Dominguez, M; Lacava, J; Langhi, M; Leone, B; Machiavelli, M; Ortiz, E; Perez, J; Rodriguez, R; Romero Acuña, J; Romero Acuña, L; Romero, A; Sabatini, C; Salvadori, M; Vallejo, C, 1996) |
| "In advanced soft tissue sarcomas of adults, single-agent doxorubicin is still the standard chemotherapy against which more intensive or new drug treatments should be compared." | 2.68 | Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. ( Buesa, J; Casali, P; Mouridsen, H; Rankin, E; Santoro, A; Somers, R; Spooner, D; Steward, W; Tursz, T; Verweij, J, 1995) |
| "Ifosfamide (5 g/m2) was compared with its parent analogue cyclophosphamide (1." | 2.67 | Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Bramwell, VH; Dombernowsky, P; Mouridsen, HT; Onsrud, M; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Verweij, J, 1993) |
| " A daily dosage of 50 to 60 mg/kg ifosfamide on 5 consecutive days produced the best results." | 2.64 | Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide. ( Brock, N; Burkert, H; Fichtner, E; Schnitker, J, 1976) |
| "Radiochemotherapy involving cisplatinum-based polychemotherapy is more toxic than radiotherapy in combination with temozolomide." | 1.48 | Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients. ( Bison, B; Bojko, S; Gielen, GH; Hoffmann, M; Kortmann, RD; Kramm, CM; Pietsch, T; Seidel, C; von Bueren, AO; Warmuth-Metz, M, 2018) |
| "Ifosfamide has been shown to be associated with encephalopathy in 10-40% of patients." | 1.43 | Severe post-treatment leukopenia associated with the development of encephalopathy following ifosfamide infusion. ( Isola, LM; Kim, SS; Oh, WK, 2016) |
| "1999 to Nov." | 1.34 | [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents]. ( Chen, XQ; Guan, ZZ; He, YJ; Lin, H; Ling, JY; Liu, DG; Luo, WB; Sun, XF; Xia, Y; Xiang, XJ; Zhen, ZJ; Zheng, L, 2007) |
| "Nine patients (100%) with metastatic breast cancer and four (67%) with soft tissue sarcoma have attained documented objective responses with four complete remissions (one breast cancer and three sarcoma patients)." | 1.29 | Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study. ( Asbury, RF; Boros, L; Chang, AY; Garrow, GC; Hui, L, 1996) |
| " For this first step a daily dosage of 300 mg/m2 of body surface resulted in only moderate leukopenia, whereas a daily dosage of 450 mg/m2 caused severe leukopenia." | 1.29 | Development of a canine chemotherapeutic model with ifosfamide. ( Chao, EY; Donehower, RC; Frassica, FJ; Ikeda, K; Inoue, N; Tomita, K, 1996) |
| " Thus, neither DSF nor DDTC impaired the antitumour effect of IFX and both diminished its adverse effects." | 1.28 | Drug interaction effects on antitumour drugs (VIII): prevention of ifosfamide-induced urotoxicity by disulfiram and its effect on antitumour activity and acute toxicity of alkylating agents in mice. ( Ishikawa, M; Sasaki, K; Takayanagi, Y, 1991) |
| "Ifosfamide was studied in advanced pancreatic tumor at the National Cancer Institute, Cairo." | 1.27 | Ifosfamide in advanced pancreatic cancer. A 5-year experience. ( Gad-el-Mawla, N, 1986) |
| "Thirty-two patients with advanced cancer were treated in a phase I-II trial with ifosfamide plus mesnum." | 1.26 | Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment. ( Falkson, G; Falkson, HC; Stapelberg, R; Van Dyk, JJ, 1982) |
| "Ifosfamide was given in i." | 1.26 | Reduction of ifosfamide toxicity using dose fractionation. ( Bodey, GP; Freireich, EJ; McCredie, KB; McKelvey, EM; Rodriguez, V; Tashima, CK, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (25.40) | 18.7374 |
| 1990's | 23 (36.51) | 18.2507 |
| 2000's | 15 (23.81) | 29.6817 |
| 2010's | 8 (12.70) | 24.3611 |
| 2020's | 1 (1.59) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, B | 1 |
| Zhang, Y | 2 |
| Li, R | 1 |
| Li, J | 1 |
| Lu, X | 1 |
| Seidel, C | 1 |
| von Bueren, AO | 1 |
| Bojko, S | 1 |
| Hoffmann, M | 1 |
| Pietsch, T | 1 |
| Gielen, GH | 1 |
| Warmuth-Metz, M | 1 |
| Bison, B | 1 |
| Kortmann, RD | 1 |
| Kramm, CM | 1 |
| Blay, JY | 1 |
| Leahy, MG | 1 |
| Nguyen, BB | 1 |
| Patel, SR | 1 |
| Hohenberger, P | 1 |
| Santoro, A | 5 |
| Staddon, AP | 1 |
| Penel, N | 1 |
| Piperno-Neumann, S | 1 |
| Hendifar, A | 1 |
| Lardelli, P | 1 |
| Nieto, A | 1 |
| Alfaro, V | 1 |
| Chawla, SP | 1 |
| Kakutani, S | 1 |
| Fukuhara, H | 1 |
| Taguchi, S | 1 |
| Nagata, M | 1 |
| Niimi, A | 1 |
| Hattori, M | 1 |
| Miyazaki, H | 1 |
| Fujimura, T | 1 |
| Nakagawa, T | 1 |
| Kume, H | 1 |
| Igawa, Y | 1 |
| Homma, Y | 1 |
| Kim, SS | 1 |
| Isola, LM | 1 |
| Oh, WK | 1 |
| Stubbe, F | 1 |
| Agaimy, A | 1 |
| Ott, O | 1 |
| Lettmaier, S | 1 |
| Vassos, N | 1 |
| Croner, R | 1 |
| Hohenberger, W | 1 |
| Fietkau, R | 1 |
| Semrau, S | 1 |
| Liu, XM | 1 |
| Wang, HQ | 1 |
| Zhang, HL | 1 |
| Qiu, LH | 1 |
| Li, W | 1 |
| Li, LF | 1 |
| Cui, XZ | 1 |
| Liu, PF | 1 |
| Hao, XS | 1 |
| Sun, XF | 3 |
| Zhen, ZJ | 3 |
| Xiang, XJ | 2 |
| Ling, JY | 3 |
| Peng, RJ | 1 |
| Xia, Y | 3 |
| Zheng, L | 2 |
| Luo, WB | 2 |
| Lin, H | 2 |
| Guan, ZZ | 2 |
| Motomura, K | 1 |
| Natsume, A | 1 |
| Fujii, M | 1 |
| Ito, M | 1 |
| Momota, H | 1 |
| Wakabayashi, T | 1 |
| Ito, Y | 1 |
| Kimura, H | 1 |
| Maeda, Y | 1 |
| Hashimoto, C | 1 |
| Ishida, F | 1 |
| Izutsu, K | 1 |
| Fukushima, N | 1 |
| Isobe, Y | 1 |
| Takizawa, J | 1 |
| Hasegawa, Y | 1 |
| Kobayashi, H | 2 |
| Okamura, S | 1 |
| Yamaguchi, M | 1 |
| Suzumiya, J | 1 |
| Hyo, R | 1 |
| Nakamura, S | 1 |
| Kawa, K | 1 |
| Oshimi, K | 1 |
| Suzuki, R | 1 |
| Luo, J | 1 |
| Wu, FY | 1 |
| Li, AW | 1 |
| Zheng, D | 1 |
| Liu, JM | 2 |
| Huang, YH | 1 |
| Wen, XP | 1 |
| Hu, L | 1 |
| Kawai, K | 1 |
| Miyazaki, J | 1 |
| Tsukamoto, S | 1 |
| Hinotsu, S | 1 |
| Hattori, K | 1 |
| Shimazui, T | 1 |
| Akaza, H | 1 |
| Song, SY | 1 |
| Kim, WS | 1 |
| Kim, K | 1 |
| Jung, CW | 1 |
| Im, YH | 1 |
| Kim, HJ | 1 |
| Kang, WK | 1 |
| Lee, HG | 1 |
| Kwon, OJ | 1 |
| Rhee, CH | 1 |
| Park, CH | 1 |
| Park, K | 1 |
| Chua, DT | 1 |
| Sham, JS | 1 |
| Au, GK | 1 |
| Fiegl, M | 1 |
| Schlemmer, M | 1 |
| Wendtner, CM | 1 |
| Abdel-Rahman, S | 1 |
| Fahn, W | 1 |
| Issels, RD | 1 |
| Lorent, N | 1 |
| De Leyn, P | 1 |
| Lievens, Y | 1 |
| Verbeken, E | 1 |
| Nackaerts, K | 1 |
| Dooms, C | 1 |
| Van Raemdonck, D | 1 |
| Anrys, B | 1 |
| Vansteenkiste, J | 1 |
| Fan, Y | 1 |
| Huang, ZY | 1 |
| Luo, LH | 1 |
| Yu, HF | 1 |
| Wang, ZH | 1 |
| Liu, DG | 1 |
| Chen, XQ | 1 |
| He, YJ | 1 |
| Falkson, G | 2 |
| Van Dyk, JJ | 1 |
| Stapelberg, R | 1 |
| Falkson, HC | 2 |
| Morgan, LR | 1 |
| Harrison, EF | 1 |
| Hawke, JE | 1 |
| Hunter, HL | 1 |
| Costanzi, JJ | 1 |
| Plotkin, D | 1 |
| Tucker, WG | 1 |
| Worrall, PM | 1 |
| Saeter, G | 1 |
| Talle, K | 1 |
| Solheim, OP | 1 |
| Haim, N | 1 |
| Ben-Shahar, M | 1 |
| Epelbaum, R | 1 |
| Tursz, T | 1 |
| Mouridsen, H | 1 |
| Verweij, J | 3 |
| Steward, W | 1 |
| Somers, R | 4 |
| Buesa, J | 1 |
| Casali, P | 1 |
| Spooner, D | 1 |
| Rankin, E | 1 |
| Dirix, LY | 1 |
| van Meerbeeck, J | 1 |
| Schrijvers, D | 1 |
| Corthouts, B | 1 |
| Prové, A | 1 |
| van Marck, E | 1 |
| Vermeire, P | 1 |
| van Oosterom, AT | 2 |
| Frustaci, S | 1 |
| Foladore, S | 1 |
| Buonadonna, A | 1 |
| De Paoli, A | 1 |
| Crivellari, D | 1 |
| Carbone, A | 1 |
| Sorio, R | 1 |
| Morassut, S | 1 |
| Monfardini, S | 1 |
| Filtenborg, TA | 1 |
| Hansen, HH | 2 |
| Aage Engelholm, S | 1 |
| Rørth, M | 1 |
| Bramwell, VH | 2 |
| Mouridsen, HT | 3 |
| Blackledge, G | 3 |
| Dombernowsky, P | 2 |
| Onsrud, M | 1 |
| Thomas, D | 3 |
| Sylvester, R | 2 |
| Chang, AY | 1 |
| Boros, L | 1 |
| Garrow, GC | 1 |
| Asbury, RF | 1 |
| Hui, L | 1 |
| Williamson, SK | 1 |
| Wolf, MK | 1 |
| Eisenberger, MA | 1 |
| O'Rourke, MA | 1 |
| Brannon, W | 1 |
| Crawford, ED | 1 |
| Ikeda, K | 1 |
| Inoue, N | 1 |
| Frassica, FJ | 1 |
| Donehower, RC | 1 |
| Tomita, K | 1 |
| Chao, EY | 1 |
| Vallejo, C | 2 |
| Romero, A | 1 |
| Perez, J | 1 |
| Cuevas, M | 1 |
| Lacava, J | 1 |
| Sabatini, C | 1 |
| Dominguez, M | 1 |
| Rodriguez, R | 1 |
| Barbieri, M | 1 |
| Romero Acuña, L | 1 |
| Romero Acuña, J | 1 |
| Langhi, M | 1 |
| Amato, S | 1 |
| Salvadori, M | 1 |
| Ortiz, E | 1 |
| Machiavelli, M | 2 |
| Leone, B | 2 |
| Hicks, LG | 1 |
| Balcerzak, SP | 1 |
| Zalupski, M | 1 |
| Chen, YM | 1 |
| Wu, MF | 1 |
| Perng, RP | 1 |
| Chou, CM | 1 |
| Yang, KY | 1 |
| Lin, WC | 1 |
| Tsai, CM | 1 |
| Whang-Peng, J | 1 |
| Lorusso, V | 1 |
| Di Vagno, G | 1 |
| Manzione, L | 1 |
| Palmeri, S | 1 |
| Nacci, G | 1 |
| Bilancia, D | 1 |
| Leonardi, V | 1 |
| Catino, A | 1 |
| Gargano, G | 1 |
| Loverro, G | 1 |
| Selvaggi, L | 1 |
| De Lena, M | 1 |
| Sculier, JP | 1 |
| Lafitte, JJ | 1 |
| Paesmans, M | 1 |
| Thiriaux, J | 1 |
| Alexopoulos, CG | 1 |
| Baumöhl, J | 1 |
| Schmerber, J | 1 |
| Koumakis, G | 1 |
| Florin, MC | 1 |
| Zacharias, C | 1 |
| Berghmans, T | 1 |
| Mommen, P | 1 |
| Ninane, V | 1 |
| Klastersky, J | 1 |
| Arland, M | 1 |
| Leuner, S | 1 |
| Lange, S | 1 |
| Bartsch, R | 1 |
| Kahl, C | 1 |
| Florschütz, A | 1 |
| Franke, A | 1 |
| Höffkes, HG | 1 |
| Edmonson, JH | 1 |
| Petersen, IA | 1 |
| Shives, TC | 1 |
| Mahoney, MR | 1 |
| Rock, MG | 1 |
| Haddock, MG | 1 |
| Sim, FH | 1 |
| Maples, WJ | 1 |
| O'Connor, MI | 1 |
| Gunderson, LL | 1 |
| Foo, ML | 1 |
| Pritchard, DJ | 1 |
| Buckner, JC | 1 |
| Stafford, SL | 1 |
| Seo, JH | 1 |
| Whang, YM | 1 |
| Kim, BS | 1 |
| Choi, CW | 1 |
| Shin, SW | 1 |
| Kim, YH | 1 |
| Kim, JS | 1 |
| Goo, BH | 1 |
| Nelson, RL | 2 |
| Creaven, PJ | 2 |
| Cohen, MH | 2 |
| Fossieck, BE | 1 |
| Schnitker, J | 1 |
| Brock, N | 1 |
| Burkert, H | 1 |
| Fichtner, E | 1 |
| Rodriguez, V | 1 |
| Bodey, GP | 1 |
| Freireich, EJ | 1 |
| McCredie, KB | 1 |
| McKelvey, EM | 1 |
| Tashima, CK | 1 |
| Allen, LM | 1 |
| Steinke, B | 1 |
| Bross, K | 1 |
| Reinold, HM | 1 |
| Heim, ME | 1 |
| Schalk, KP | 1 |
| Heidemann, E | 1 |
| Josten, K | 1 |
| Arnold, H | 1 |
| Manegold, C | 1 |
| Hoffman, I | 1 |
| Lund, B | 1 |
| Hansen, OP | 1 |
| Hansen, M | 1 |
| Kuehnle, H | 1 |
| Meerpohl, HG | 1 |
| Eiermann, W | 1 |
| Achterrath, W | 1 |
| Arai, N | 1 |
| Hara, A | 1 |
| Umeda, M | 1 |
| Shirai, T | 1 |
| Ishikawa, M | 1 |
| Takayanagi, Y | 1 |
| Sasaki, K | 1 |
| Lokich, I | 1 |
| Anderson, N | 1 |
| Bern, M | 1 |
| Moore, C | 1 |
| Schütte, J | 1 |
| Stewart, W | 1 |
| Itami, S | 1 |
| Ogawa, M | 1 |
| Horikoshi, N | 1 |
| Inoue, K | 1 |
| Mukaiyama, T | 1 |
| Fukutani, H | 1 |
| Tabata, M | 1 |
| Hirano, A | 1 |
| Mizunuma, N | 1 |
| Nakagawa, K | 1 |
| Chasen, MR | 1 |
| Satoh, H | 1 |
| Yano, H | 1 |
| Naitoh, T | 1 |
| Suyama, T | 1 |
| Takahashi, N | 1 |
| Kameyama, M | 1 |
| Satoh, T | 1 |
| Ohtsuka, M | 1 |
| Yoshizawa, Y | 1 |
| Hasegawa, S | 1 |
| Wiltshaw, E | 1 |
| Westbury, G | 1 |
| Harmer, C | 1 |
| McKinna, A | 1 |
| Fisher, C | 1 |
| Van Oosterom, A | 1 |
| Gad-el-Mawla, N | 1 |
| Ghosn, M | 1 |
| Droz, JP | 1 |
| Theodore, C | 1 |
| Pico, JL | 1 |
| Baume, D | 1 |
| Spielmann, M | 1 |
| Ostronoff, M | 1 |
| Moran, A | 1 |
| Salloum, E | 1 |
| Kramar, A | 1 |
| Nishida, T | 1 |
| Nagasue, N | 1 |
| Brade, W | 1 |
| Seeber, S | 1 |
| Herdrich, K | 1 |
| Einhorn, LH | 2 |
| Loehrer, PJ | 1 |
| Hoefer, H | 1 |
| Scheef, W | 1 |
| Titscher, R | 1 |
| Kokron, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) Versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients With Translocation-Related Sarcomas (TRS)[NCT00796120] | Phase 3 | 121 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial[NCT02531841] | Phase 3 | 250 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| A Phase Ⅱ Single-arm Clinical Trial to Investigate the Efficacy and Safety of Vinorelbine-ifosfamide Regimen as Third-line Treatment in Refractory or Recurrent Extensive Small Cell Lung Cancer Patients[NCT01752517] | 60 participants (Anticipated) | Observational | 2012-12-31 | Recruiting | |||
| A Phase II Multicenter Trial of RAD001 in Patients With Metastatic or Recurrent Sarcomas[NCT01830153] | Phase 2 | 41 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study[NCT01136499] | Phase 2 | 53 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Phase II Prospective Study With BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas, After Anthracycline-based Therapy[NCT00406601] | Phase 2 | 69 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Comparing the Effectiveness and Toxicity for Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Patients Who Had Received Total Dose of Anthracycline Antibiotics More Than 300mg/m2 With Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus[NCT03342300] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2017-11-06 | Withdrawn (stopped due to No participants enrolled) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of participants survived for 6 months from the start of study treatment without progression of disease. Progression of the disease was associated with increasing symptoms, including pain from new or progressing lesions. Delay in disease progression generally represents a clinical benefit to the participant. (NCT00796120)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Trabectedin | 66.7 |
| Doxorubicin Plus Ifosfamide | 78.3 |
The DOR is defined as the time from date of first documentation of response (CR or PR, whichever comes first) to the date of documented PD or death. PR=at least 30% reduction in the sum of the longest dimensions (LD) of all target lesions in reference to the baseline sum LD, CR =Disappearance of all non-target lesions. (NCT00796120)
Timeframe: Up to 20 months
| Intervention | days (Median) |
|---|---|
| Trabectedin | NA |
| Doxorubicin Plus Ifosfamide | NA |
Overall survival defined as time from the date of randomization to the date of death. For participants who were alive at the time of analysis, overall survival was censored at the last contact date. (NCT00796120)
Timeframe: Baseline up to End of Study (an average of 4 years)
| Intervention | months (Median) |
|---|---|
| Trabectedin | 46.6 |
| Doxorubicin Plus Ifosfamide | 33.5 |
Tumor response was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Partial Response (PR)=at least 30% reduction in the sum of the longest dimensions (LD) of all target lesions in reference to the baseline sum LD, Complete Response (CR) =Disappearance of all non-target lesions. Percentage of participants with objective tumor response was determined by the number of participants with PR or CR divided by the total number of response-evaluable participants. (NCT00796120)
Timeframe: Every 6 weeks during first 9 months of the study and thereafter every 9 weeks up to 20 months
| Intervention | percentage of participants (Number) |
|---|---|
| Trabectedin | 5.9 |
| Doxorubicin Plus Ifosfamide | 27.0 |
The PFS was assessed as median number of days from the date of randomization until the first documented sign of disease progression (increase in disease; radiographic, clinical, or both) or death due to any cause, whichever occurred earlier. (NCT00796120)
Timeframe: Every 6 weeks from randomization during the first 9 months and thereafter, every 9 weeks up to 20 months
| Intervention | months (Median) |
|---|---|
| Trabectedin | 19.6 |
| Doxorubicin Plus Ifosfamide | 8.3 |
3 reviews available for ifosfamide and Leukocytopenia
| Article | Year |
|---|---|
The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Do | 2020 |
Neoadjuvant therapy for cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1992 |
Comparative activity of ifosfamide and cyclophosphamide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cystitis; Humans; Ifosfam | 1986 |
31 trials available for ifosfamide and Leukocytopenia
| Article | Year |
|---|---|
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Adm | 2014 |
[DNCE regimen for treatment of refractory or relapsed aggressive and highly aggressive non-Hodgkin lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 2008 |
[Efficacy of modified B-NHL-BFM-90 protocol on anaplastic T-cell lymphoma in children and adolescents].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2009 |
Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; DNA, Viral; E | 2012 |
[Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Fem | 2002 |
Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Admini | 2003 |
A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp | 2004 |
Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Th | 2004 |
Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2004 |
Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cispl | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Feasibility Studies; Femal | 1994 |
Epirubicin and ifosfamide in advanced soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Feasibility Stu | 1993 |
A phase II study of ifosfamide, carboplatin and cisplatin in advanced and recurrent squamous cell carcinoma of the uterine cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1993 |
Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group.
Topics: Adolescent; Adult; Aged; Chi-Square Distribution; Cyclophosphamide; Female; Humans; Ifosfamide; Leuk | 1993 |
Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; B | 1996 |
Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 1996 |
GM-CSF did not allow doxorubicin dose escalation in the MAID regimen: a phase I trial. A Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dacarbazine; Doxorubicin; Granulocyte-M | 1996 |
Phase II study of ifosfamide and etoposide chemotherapy for extensive-disease small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Small Cell; Drug Admin | 1997 |
Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. GOCS (Gynecological Oncology Cooperative Study).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carb | 1998 |
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-S | 2000 |
Ifosamide, epirubicin and granulocyte colony-stimulating factor: a regimen for successful mobilization of peripheral blood progenitor cells in patients with multiple myeloma.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2001 |
Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2002 |
A Phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Pro | 2002 |
Phase I clinical trial of a 3-day divided dose schedule of ifosfamide (NSC 109724).
Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Hematuria; Humans; Ifosfamide; Kidney Tubul | 1976 |
Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Breast Neoplasms; Child; Clinical Trials as Topic; Cyclopho | 1976 |
Cyclic alternating chemotherapy of high-grade malignant non-Hodgkin lymphomas with VIM-Bleo and CHOP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1992 |
Neoadjuvant therapy for cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1992 |
Ifosfamide continuous infusion without mesna. A phase I trial of a 14-day cycle.
Topics: Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Hematuria; Humans; Ifosfamide; I | 1991 |
Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Infections; | 1986 |
[Treatment of bronchogenic cancer and lung metastases of solid tumors with ifosfamid (author's transl)].
Topics: Carcinoma, Bronchogenic; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Female; Humans | 1974 |
30 other studies available for ifosfamide and Leukocytopenia
| Article | Year |
|---|---|
Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chil | 2018 |
Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Doce | 2015 |
Severe post-treatment leukopenia associated with the development of encephalopathy following ifosfamide infusion.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Female; Humans; Ifosf | 2016 |
Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Doxorubici | 2016 |
Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous Sy | 2011 |
Comparison of vinorelbine, ifosfamide and cisplatin (NIP) and etoposide and cisplatin (EP) for treatment of advanced combined small cell lung cancer (cSCLC) patients: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2012 |
Vinorelbine, ifosfamide, and cisplatin combination as salvage chemotherapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2003 |
[MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Drug Resistance, Neo | 2005 |
[Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma].
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carbo | 2006 |
[Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, P | 2007 |
Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.
Topics: Adult; Aged; Cyclophosphamide; Female; Humans; Ifosfamide; Kidney Diseases; Leukopenia; Male; Mercap | 1982 |
Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study.
Topics: Alopecia; Brain; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation; Hematuria; Humans; | 1982 |
Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Etoposide; Female; F | 1995 |
Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agen | 1996 |
Development of a canine chemotherapeutic model with ifosfamide.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood Platelets; Bone Neoplasms; Dogs; Drug Administrati | 1996 |
Reduction of ifosfamide toxicity using dose fractionation.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Administration Schedule; Female; Hematuria; Humans; | 1976 |
Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724).
Topics: Alkylation; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug E | 1976 |
Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Administra | 1992 |
[Salvage chemotherapy with IMV-triple P for relapsed or refractory malignant lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation; Female; Hea | 1991 |
Drug interaction effects on antitumour drugs (VIII): prevention of ifosfamide-induced urotoxicity by disulfiram and its effect on antitumour activity and acute toxicity of alkylating agents in mice.
Topics: Animals; Disulfiram; Ditiocarb; Dose-Response Relationship, Drug; Ifosfamide; Leukopenia; Male; Mice | 1991 |
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluatio | 1990 |
[Combination chemotherapy of ifosfamide, cisplatin and vindesine for non-small cell lung cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1990 |
Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small | 1990 |
[A case of retrocecal appendicitis occurrence during effective chemotherapy in lung cancer].
Topics: Abscess; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Appendicitis; Bone Marrow; | 1989 |
Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pre | 1986 |
Ifosfamide in advanced pancreatic cancer. A 5-year experience.
Topics: Adult; Alopecia; Anemia; Drug Evaluation; Female; Humans; Ifosfamide; Leukopenia; Male; Mesna; Middl | 1986 |
Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Etopo | 1988 |
Treatment of gynecological adenocarcinomas with a combination of ifosfamide, adriamycin and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1988 |
VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Humans; Ifosfamide; Kidn | 1986 |
Ifosfamide chemotherapy for pancreatic carcinoma.
Topics: Acetylcysteine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfam | 1986 |